SAMSUNG BIOLOGICS acquires Human Genome Sciences

SAMSUNG BIOLOGICS agreed to acquire Human Genome Sciences. Reported deal value: $280M. Status: Pending. Sector: biopharmaceutical. Target headquarters context: Location not specified.

This page summarizes publicly available information about the transaction as of 2026-01-08. Figures and status may change as filings and press coverage update.

Published: 8-Jan-2026 Design & Build Hi Tech Manufacturing Pharmaceutical The US subsidiary Samsung Biologics America has entered into a $280m agreement with GSK to acquire its Human Genome Sciences facility Samsung Biologics has secured its first domestic biologics manufacturing site in the US by acquiring Human Genome Sciences from GlaxoSmithKline